Documented formulation project · 02
FolliGenz Aminexil 2% + Encapsulated Retinol + MCT C6/C8 Low-Ethanol Scalp Serum
How Biotica Consulting translated a multi-pathway scalp-care hypothesis into a pilot-ready formula and documentation program for FolliGenz and Hemu Haohai. The resulting Aminexil C6/C8 product appears in the signed quality record as Scalp Essence and in listing records as FluxArco ANTI-HAIR LOSS ESSENCE LIQUID.
- Organizations
- FolliGenz Therapeutics Corporation × Nanjing Hemu Haohai Biotechnology Co., Ltd.
- Project period
- Documentation dated May–July 2026
- Prepared by
- Biotica Consulting LLC
- Last reviewed
- August 7, 2026
- Status
- Prototype, signed quality documentation, and listing support
- Format
- Cross-border formulation development
This is a documented project case study. Biotica Consulting LLC provided scientific research and formulation-development support for FolliGenz Therapeutics Corporation. Hemu Haohai served as the China-side manufacturing interface and coordinated samples. The supplied quality and listing records document this Aminexil 2% + encapsulated retinol + C6/C8 MCT product under the quality-record name Scalp Essence and the listed name FluxArco ANTI-HAIR LOSS ESSENCE LIQUID. Private correspondence, commercial terms, the complete confidential manufacturing formula, the facility FEI, and the product-listing number are not published.
The development question and the work behind it
FolliGenz wanted a daily leave-on scalp serum that did more than place a single active in a conventional high-alcohol vehicle. Biotica Consulting evaluated a complementary design built around 2% Diaminopyrimidine Oxide, commonly marketed as Aminexil and selected to help maintain a flexible scalp and perifollicular environment, alongside a C6/C8 medium-chain triglyceride phase, encapsulated retinol, and a broad hydration and comfort system in a low-ethanol vehicle.
Biotica converted that concept into an OEM implementation package covering phase architecture, a scaled manufacturing sequence, process guardrails, pilot-release criteria, protective packaging, stability and microbiology expectations, and careful claim boundaries. FolliGenz directed product and commercialization decisions, while Hemu Haohai served as the China-side interface for factory feasibility, prototype handling, documentation questions, and sample logistics. Later supplied records document batch-quality checks and a MoCRA-related facility and product listing handoff. According to the project team, stability testing supported a reported 24-month product life. The underlying protocol and report were not supplied for this public update, so that result is presented as project-reported and is not inferred from the COA or registration document.
Defined roles across the project
Biotica Consulting LLC
Reviewed the mechanistic literature, separated plausible formulation rationale from unproven claims, designed the formula architecture, and prepared the OEM handoff process, specification, packaging, and validation brief.
FolliGenz Therapeutics Corporation
Defined the product direction and constraints, reviewed development decisions, and coordinated quality, stability, packaging, scale, and commercialization questions with manufacturing partners.
Nanjing Hemu Haohai Biotechnology Co., Ltd.
Relayed factory feasibility, arranged prototype and sample work, and supported documentation, packaging, and logistics discussions during the development handoff.
A traceable development path
- 01
Product listing documentation recorded
A supplied third-party registration-agent record documents this product under its listed name, FluxArco ANTI-HAIR LOSS ESSENCE LIQUID, at Guangzhou Huaxia Biopharmaceuticals. It records a MoCRA-related facility and cosmetic product-listing handoff. It is a listing record, not FDA approval.
- 02
Production brief issued
Biotica documented the target composition, manufacturing sequence, process controls, packaging requirements, and release and stability expectations in a pilot-evaluation technical brief.
- 03
Factory feasibility, samples, and signed batch documentation
FolliGenz and Hemu Haohai exchanged manufacturing, sample, package, documentation, shelf-life, and scale questions. The supplied signed Scalp Essence inspection COA dated July 2026 records batch identity, organoleptic observations, pH, short physical-stress checks, microbial counts, and an overall passing conclusion for this product.
- 04
24-month stability outcome reported
The supplied project photo records pilot samples, and the project team reports that stability testing supported a 24-month product life. The underlying report was not included in the materials reviewed for this public update, and the short COA checks shown below are not a substitute for it.
From formulation brief to documented product controls
The supplied project record extends from formulation research into a signed Scalp Essence inspection COA and the product listing for FluxArco ANTI-HAIR LOSS ESSENCE LIQUID. These are quality-record and listing names for the Aminexil 2% + encapsulated retinol + C6/C8 MCT product documented in this case study. Selected pages are reproduced below as WebP images without posting source PDFs, protected listing identifiers, or private contact details.
According to the project team, stability testing supported a reported 24-month product life. The underlying 24-month protocol and report were not among the records reviewed for this update. The signed inspection COA shown here documents July 2026 batch QC and short physical-stress checks; it does not by itself establish the two-year outcome.
The supplied registration-agent page documents this product under the listed name FluxArco ANTI-HAIR LOSS ESSENCE LIQUID at Guangzhou Huaxia Biopharmaceuticals. It is third-party documentation associated with a MoCRA facility-registration and product-listing handoff. The document itself states that it does not represent FDA endorsement, and FDA explains that cosmetic registration and listing are not an approval program.
Related FDA Cosmetics Direct screenshots supplied with the project show the submission as Submission Accepted and the product as Listed with an effective date of May 26, 2026. Those portal statuses record completion of the listing submission workflow. They do not show FDA review or approval of safety, efficacy, claims, formula, or shelf life, and the unredacted portal screenshots are not reproduced publicly.
Scalp Essence batch inspection and release record
The signed and stamped Guangzhou Huaxia inspection report identifies Scalp Essence, batch HXLJ26071002, with production and inspection dated July 13 and reporting dated July 20, 2026. The 300 g sample records pH 5.5, conforming organoleptic observations, normal heat, cold, and centrifuge checks, microbial results below 10 CFU/g, and an overall Qualified conclusion. Scalp Essence is the quality-record name for the Aminexil 2% + encapsulated retinol + C6/C8 MCT product documented here.
Agent-issued MoCRA registration and listing record
This record was issued by Shenzhen CDT Testing, not by FDA. It documents this product under the listed name FluxArco ANTI-HAIR LOSS ESSENCE LIQUID at Guangzhou Huaxia Biopharmaceuticals and disclaims FDA endorsement. The public copy withholds the facility FEI, product-listing number, street address, agent identity and signature, contact details, and private certificate dates. FDA does not issue certificates for cosmetic facility registrations or product listings.
Identity, organoleptic checks, and pH
The accompanying English COA presentation uses the shortened name Scalp Serum for the same document number, batch, and dates shown on the signed Scalp Essence inspection report. It records consistent color, odor, and appearance with a measured pH of 5.5 at 25 °C.
Physical stability and microbial observations
The accompanying English COA presentation records normal results after 24 hours at 40 ± 1 °C, after 24 hours at −8 ± 2 °C, and after a separate 30-minute centrifugation check at 2,000 r/min. Total aerobic microbial count and total yeast and mold count were each below 10 CFU/g. These are batch-level checks, separate from the reported 24-month stability dataset.
Documentation note: the signed and stamped source report uses Scalp Essence, while the accompanying English presentation uses the shortened name Scalp Serum. The signed source controls. FluxArco ANTI-HAIR LOSS ESSENCE LIQUID is the product-listing name. These records cover the Aminexil 2% + encapsulated retinol + C6/C8 MCT product documented in this case study.
Questions the work was designed to answer
- How can a highly water-compatible Aminexil phase and a lipid-dependent retinol system coexist in a stable, low-ethanol leave-on emulsion?
- Can the lipid phase prioritize light feel and retinol delivery while avoiding overstatement of an antifungal effect?
- Which hydration and soothing components make repeated use more practical without relying on propylene glycol, fragrance, menthol, or a high alcohol load?
- What process controls, package choices, and release tests should an OEM receive before scale-up?
What the project record supports
Aminexil was selected to support a flexible scalp environment
Biotica traced Aminexil to 2,4-diaminopyrimidine 3-oxide and reviewed foundational in-vitro work on lysyl-hydroxylase expression. That research informed its inclusion to help maintain a flexible scalp and perifollicular environment around the follicle.
The vehicle was designed as part of the product strategy
The formula combines a dissolved aqueous active with a protected C6/C8 lipid phase and encapsulated retinol in a light, low-ethanol milky emulsion. The complete composition, supplier specifications, and processing parameters remain confidential.
MCT is a carrier first and a microbiome-conscious hypothesis second
C6/C8 MCT carries the retinol phase, improves spread, and avoids heavier long-chain oils. Laboratory literature provides a reason to test a secondary yeast-environment hypothesis, but species, concentration, free-fatty-acid content, topical conditions, and finished-formula behavior matter. The finished emulsion is not presented as an antifungal treatment.
Encapsulation supports controlled handling, not automatic efficacy
Encapsulated retinol was selected to reduce direct exposure and improve handling of a light- and oxygen-sensitive material. Cool-down addition, limited post-addition shear, antioxidant and chelator support, and opaque airless packaging were built into the transfer plan. Retinol retention, carrier integrity, and active-content verification still require suitable supplier and finished-product data.
Tolerability was treated as a development requirement
A broad humectant and comfort system, low ethanol, and exclusions for propylene glycol, polypropylene glycol, fragrance, essential oils, and menthol were chosen to make routine use more plausible. These choices do not replace finished-product irritation or use testing.
The handoff defined what must be proven next
Biotica specified pilot-release targets, protective packaging, microbial and preservative testing, accelerated and real-time stability, and active verification. The project team later reported stability testing supporting a 24-month product life, but the underlying protocol and report were not supplied for this public update. Separate comparative studies would still be needed to establish any Aminexil–MCT additive effect or Malassezia-related claim.
The signed Scalp Essence COA documents batch release checks
The signed July 2026 Scalp Essence inspection COA records pH 5.5, passing organoleptic observations, normal results after the specified 24-hour hot and cold holds, a separate 30-minute centrifugation check at 2,000 r/min, and total aerobic plus yeast and mold counts each below 10 CFU/g. It also records an overall passing conclusion for the inspected batch. These release checks support the quality record for this Aminexil C6/C8 product and remain separate from the reported 24-month stability study.
A cosmetic listing record is not FDA approval
The supplied third-party registration-agent record documents this product's MoCRA facility-registration and product-listing handoff at Guangzhou Huaxia Biopharmaceuticals under the listed name FluxArco ANTI-HAIR LOSS ESSENCE LIQUID. FDA states that cosmetic product facility registration and product listing are not an approval program and that FDA does not issue certificates for cosmetic product facility registrations or product listings. The record does not establish FDA review of the formula, safety, efficacy, claims, or stability.
What must be proven before stronger claims
The project record is a development input, not permission to outrun the evidence. These are the next questions for direct testing and review.
- Can the complete 24-month stability protocol and signed report be matched to the exact formula version, batch, package, storage conditions, timepoints, methods, assays, acceptance criteria, and conclusion?
- Does Aminexil remain fully dissolved through real-time, accelerated, freeze-thaw, and package-compatibility studies?
- Does the encapsulated-retinol system retain active content and delivery integrity throughout the intended shelf life?
- Does the preserved finished emulsion pass microbial limits and a suitable preservative challenge test?
- Do the selected airless components protect the product and dispense the intended dose consistently?
- Does repeat-use tolerability support the proposed directions in the target population?
- Can any microbiome or Malassezia language be supported by a finished-product study against relevant species and a matched vehicle?
- Have cosmetic, medical, trademark, and market-specific claims been reviewed for each intended jurisdiction?
Progress stated at the level the work supports
Biotica's contribution was the disciplined bridge between an interesting biological concept and a buildable development package. The record now includes pilot samples, a client-reported 24-month stability outcome, a signed Scalp Essence batch inspection COA, and the product's FluxArco regulatory-listing handoff. Together, these records show the path from formulation rationale through manufacturing coordination, documented quality review, and listing support.
Hemu Haohai connected ingredient sourcing to an executable OEM path
FolliGenz and Biotica worked with Nanjing Hemu Haohai Biotechnology as the China-side formulation, API supply, and OEM coordination partner for this program.
The collaboration connected active and excipient research with factory feasibility, prototype preparation, packaging, quality documentation, stability planning, and international logistics. It is a practical example of how API supply intelligence moves from source research into a finished-product development path.
Project records and public sources
The signed and stamped Scalp Essence inspection report and selected supporting pages are reproduced as public-safe WebP images. Facility FEI, product-listing number, street address, and private agent details remain withheld. The full PDFs, correspondence, and confidential formula are not posted; the underlying 24-month stability protocol and report were not supplied for this public update. Public literature informed the development rationale; none of the cited papers tests this exact finished formula.
- 01Private project record
Final Production Formula v1.0
FolliGenz project record · Confidential manufacturing brief
- 02Private project record
FolliGenz–Hemu Haohai development correspondence
Supplied project record · Private correspondence · July 2026
- 03Private project record
24-month stability outcome update
FolliGenz project record · Client-provided project update
- 04Signed report and supporting pages shown above
Signed Semi-Finished Product Inspection Report: Scalp Essence, HX-RE-QA-026
Guangzhou Huaxia Biopharmaceuticals Co., Ltd. · Signed and stamped batch QC record · July 2026
- 05Redacted first page shown above
Third-party cosmetic facility and product-listing record
Shenzhen CDT Testing Technology Co., Ltd. · Registration-agent record · May 2026
- 06Private project record
Cosmetics Direct submission and product-listing screenshots
Supplied project documentation · Portal records · May 26, 2026
- 07View source
Registration and Listing of Cosmetic Product Facilities and Products
U.S. Food and Drug Administration · Official FDA guidance
- 08View source
Does FDA approve cosmetics before they go on the market?
U.S. Food and Drug Administration · Official FDA explainer
- 09View source
FolliGenz Therapeutics: About Us
FolliGenz Therapeutics Corporation · Official company page
- 10View source
Nanjing Hemu Haohai Biotechnology
Nanjing Hemu Haohai Biotechnology Co., Ltd. · Official company site
- 11View source
A minoxidil-related compound lacking a C6 substitution still inhibits lysyl hydroxylase gene expression in vitro
PubMed · Peer-reviewed mechanistic study
- 12View source
Perifollicular fibrosis: pathogenetic role in androgenetic alopecia
PubMed · Peer-reviewed human tissue study
- 13View source
Medium-chain triglycerides inhibit growth of Malassezia
PubMed · Peer-reviewed in-vitro study
- 14View source
Analysis of Malassezia lipidome disclosed differences among species and strains
Frontiers in Cellular and Infection Microbiology · Peer-reviewed lipidomics study
- 15View source
The effect of medium-chain triglycerides oil on Candida albicans
PubMed · Peer-reviewed experimental study
- 16View source
Encapsulation and controlled release of retinol from silicone particles for topical delivery
PubMed · Peer-reviewed delivery study
Project evidence and literature must be read within their stated methods and limitations. This page is not medical, clinical, regulatory, or legal advice.
Related projects and research
Follow adjacent formulation, partner, supplier, and research questions while keeping each evidence type clearly labeled.
Need a development question turned into a testable brief?
Biotica can connect literature review, formulation strategy, partner coordination, market analysis, and a validation roadmap around the decision your team needs to make.
Discuss a development project